Previous Close | 3.1800 |
Open | 3.1400 |
Bid | 4.0100 x 1400 |
Ask | 4.8400 x 1200 |
Day's Range | 2.9300 - 3.2490 |
52 Week Range | 1.6000 - 8.4800 |
Volume | |
Avg. Volume | 206,701 |
Market Cap | 40.364M |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.0000 |
Earnings Date | Apr 24, 2024 - Apr 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for CASI
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of FOLOTYN® (Pralatrexate Injection) to a patient in China. This remarks a pivotal step in CASI's commitment to addressing critical medical needs in peripheral T-cell lymphoma in China market.
Despite an already strong run, CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shares have been powering on, with a gain of...